Guggenheim Maintains Buy on Nanobiotix, Raises Price Target to $36

Benzinga Newsdesk www.benzinga.com Positive 74.5%

Neg 0% Neu 0% Pos 74.5%

Guggenheim analyst Michael Schmidt maintains Nanobiotix (NASDAQ:NBTX) with a Buy and raises the price target from $26 to $36.